MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, KPTI had -$1,923K decrease in cash & cash equivalents over the period. -$75,369K in free cash flow.

Cash Flow Overview

Change in Cash
-$1,923K
Free Cash flow
-$75,369K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Loss (gain) on extinguishment of...
    • Proceeds from maturities of inve...
    • Accrued expenses and other liabi...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Payment of debt and equity issua...
    • Accounts payable
    • Others

Cash Flow
2025-12-31
Net loss
-196,039
Stock-based compensation expense
14,050
Depreciation and amortization
296
Amortization of debt issuance costs and discounts
10,546
Interest expense added to debt principal
6,258
Net amortization of premiums and discounts on investments
410
Loss (gain) on extinguishment of debt
-62,365
Change in fair value of embedded derivatives and common stock warrants
707
Accounts receivable, net
-4,588
Inventory
-701
Prepaid expenses and other assets
-4,126
Operating lease right-of-use assets
-1,336
Accounts payable
-1,104
Accrued expenses and other liabilities
19,063
Operating lease liabilities
-438
Net cash used in operating activities
-75,369
Proceeds from maturities of investments
43,378
Purchases of investments
0
Purchases of property and equipment
0
Net cash provided by investing activities
43,378
Proceeds from convertible debt
15,000
Proceeds from senior secured term loan
12,250
Proceeds from issuance of common stock and warrants in private placement offering
8,750
Proceeds from the exercise of stock options and shares issued under the employee stock purchase plan
761
Payment of convertible debt
250
Payment of deferred royalty obligation
0
Payment of debt and equity issuance costs
6,463
Net cash provided by financing activities
30,048
Effect of exchange rates on cash, cash equivalents and restricted cash
20
Net (decrease) increase in cash, cash equivalents and restricted cash
-1,923
Cash and cash equivalents at beginning of period
62,814
Cash and cash equivalents at end of period
60,891
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof investments$43,378K Proceeds fromconvertible debt$15,000K Proceeds from seniorsecured term loan$12,250K Proceeds from issuance ofcommon stock and...$8,750K Proceeds from theexercise of stock options...$761K Net cash provided byinvesting activities$43,378K Net cash provided byfinancing activities$30,048K Effect of exchangerates on cash, cash...$20K Canceled cashflow$6,713K Net (decrease)increase in cash, cash...-$1,923K Canceled cashflow$73,446K Loss (gain) onextinguishment of debt-$62,365K Accrued expenses andother liabilities$19,063K Stock-based compensationexpense$14,050K Amortization of debt issuancecosts and discounts$10,546K Interest expense added todebt principal$6,258K Accounts receivable, net-$4,588K Prepaid expenses andother assets-$4,126K Operating leaseright-of-use assets-$1,336K Inventory-$701K Depreciation andamortization$296K Payment of debt andequity issuance costs$6,463K Payment of convertibledebt$250K Net cash used inoperating activities-$75,369K Canceled cashflow$123,329K Net loss-$196,039K Accounts payable-$1,104K Change in fair value ofembedded derivatives and...$707K Operating leaseliabilities-$438K Net amortization ofpremiums and discounts on...$410K

Karyopharm Therapeutics Inc. (KPTI)

Karyopharm Therapeutics Inc. (KPTI)